Know Cancer

forgot password

Vascular-Targeted Photodynamic Therapy Using WST 11 in Patients With Localized Prostate Cancer

Phase 2
18 Years
Not Enrolling
Prostate Cancer

Thank you

Trial Information

Vascular-Targeted Photodynamic Therapy Using WST 11 in Patients With Localized Prostate Cancer

This trial is designed as a multicentre, phase II, open-labeled, single intra-venous (IV)
dose study. The patient is to receive general anesthesia. WST11-mediated VTP will consist of
the combination of a single IV administration of WST11 at doses of 2 mg/Kg,4mg/Kg and 6
mg/kg, using 753 nm laser light at a fixed power (150mW/cm) and energy (200 J/cm) delivered
through transperineal interstitial optical fibers. If deemed necessary and in consideration
of the results of the patients treated with 200 J/cm, alternate power (200mW/cm) and
alternate energy (300 J/cm) might be applied after Sponsor, Steering Committee and DSMB
approval.The fibers are introduced into transparent needles that are positioned in the
prostate under ultra sound image guidance (using a brachytherapy like template). The tumor
location is established using transrectal biopsy and MR imaging. The number of fibers and
the total light energy will be adapted to each patient, taking into account the tumor
localization and the volume of the prostate.

Inclusion Criteria:

- Diagnosed with prostate cancer and eligible for active surveillance;

- No prior treatment for prostate cancer;

- Prostate Cancer Stage up to cT2b - N0/Nx - M0/Mx (rT2c and pT2c are acceptable);

- Gleason score ≤ 3+3 For patients characterized with prostate mapping (transperineal
template guided biopsy at 5mm intervals) a secondary pattern 4 is acceptable provided
that it is not present in more than 3 cores from each side of the prostate and is no
more than 3 mm cancer core length.

- PSA < 10 ng/mL;

Exclusion Criteria:

- Any condition or history of illness or surgery that, in the opinion of the
investigator and/or the Sponsor, might confound the results of the study or pose
additional risks to the patient.

- Patients with a prior history of viral or alcoholic hepatitis, and other patients
felt to be at risk for hepatotoxicity including concomitant use of potentially
hepatotoxic medications or dietary supplements;

- History of non compliance with medical therapy and medical recommendations or an
unwillingness or inability to complete patient self-administered questionnaires;

- Participation in a clinical study or receipt of an investigational treatment within
the past 3 months;

- A history of porphyria;

- Patient with contra-indication to MRI (such as pace maker, metal prosthesis, etc.);

- All patients whose current pre-operative cardiac evaluation does not show their
fitness for a procedure requiring general anesthesia;

- Patients with a history of inflammatory bowel disease or other factors which may
increase the risk of fistula formation;

- Men who have received any hormonal manipulation (excluding 5-alpha reductase
inhibitors) or androgen supplements within the previous 6 months;

- Men previously treated by radiation therapy (external therapy or brachytherapy) or
chemotherapy or any therapy for prostate cancer;

- Men who have received or are receiving chemotherapy for prostate carcinoma or other
significant cancer;

- Men who have undergone previous TURP (trans-urethral resection of the prostate);

- Men who are currently receiving any medications having potential photosensitizing
effects (e.g. tetracyclines, sulfonamides, phenothiazines, sulfonylurea hypoglycemic
agents, thiazide diuretics and griseofulvin);

- Men who are receiving anticoagulant drugs (e.g.: coumadin, warfarin)

- Patient who stopped long term treatment of acetylsalicylic acid (aspirin) or other
anti platelets agents less than 15 days before the procedure;

- Patient suspected of Disseminated Intravascular Coagulation (DIC) as defined by the
presence of three out of the five following criteria: platelets ULN,aPTT
>ULN, fibrinogenULN;

- A history of sun hypersensitivity or photosensitive dermatitis;

- Renal disorders (blood creatinine > 1.5 x ULN) or known post mictional residue >

- Hepatic disorders (transaminases > ULN, bilirubin > ULN). In case of slight
abnormalities, another exam should be performed. If the results are within normal
ranges, then the patient can be included;

- Hematological disorders (white cells < 2500/mm3, neutrophils < 1500/mm3, platelets <
140.000/mm3, Hb < 8 g/dl);

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Negative biopsy in the treated lobe

Outcome Time Frame:

Month 6

Safety Issue:


Principal Investigator

Mark EMBERTON, Professor

Investigator Role:

Principal Investigator

Investigator Affiliation:

Urology Directorate


France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Study ID:

CLIN801 PCM201



Start Date:

September 2008

Completion Date:

July 2012

Related Keywords:

  • Prostate Cancer
  • Prostatic disease
  • genital neoplasm, male
  • Urogenital neoplasm
  • Genital disease
  • male
  • Male urogenital disease
  • Neoplasms
  • Neoplasm by site
  • prostatic neoplasm
  • Carcinoma
  • Prostatic Neoplasms